Overall, treatment of COVID-19-related TMA was directed by the underlying pathophysiology of the disease, with the main recognized mechanisms of TMA in patients with COVID 19 being complement-mediated disease and acquired ADAMTS13 deficiency. Here, ADAMTS13 is linked to COVID-19.